Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toripalimab - Shanghai Junshi Biosciences

Next Previous
Drug Profile

Toripalimab - Shanghai Junshi Biosciences

Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi Biosciences; CHS-007; JS 001; JS-001sc; LOQTORZI; SO-001; TAB-001; Terepril monoclonal antibody; toripalimab-tpzi; Treipril monoclonal antibody; Treprizumab; Treprizumab - Shanghai Junshi Biosciences; Tripleitriumab; Triprizumab; Tuoyi

Latest Information Update: 09 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elpiscience Biopharmaceuticals; Shanghai Junshi Biosciences
  • Developer Ascentage Pharma; Coherus BioSciences; Fudan University; GenFleet Therapeutics; HUTCHMED; I-MAB Biopharma; Peking Union Medical College Hospital; Peking University; RemeGen; Shanghai Junshi Biosciences; Sun Yat-Sen University; Suzhou Yasheng Pharmaceutical; Xiangya Hospital of Central South University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nasopharyngeal cancer; Malignant melanoma; Oesophageal cancer; Small cell lung cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer; Urogenital cancer
  • Registered Renal cancer
  • Preregistration Small cell lung cancer; Triple negative breast cancer
  • Phase III Gastric cancer; Hodgkin's disease; Liver cancer; Neuroendocrine tumours
  • Phase II Biliary cancer; Bladder cancer; Cancer; Colorectal cancer; Solid tumours; Thyroid cancer
  • Phase I/II Head and neck cancer; Liposarcoma; Lung cancer
  • No development reported Alveolar soft part sarcoma; Lymphoma

Most Recent Events

  • 07 Apr 2024 Registered for Renal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV)
  • 06 Feb 2024 Launched for Non-small cell lung cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in China (IV) before January 2024
  • 06 Feb 2024 Launched for Non-small cell lung cancer (Late-stage disease, Monotherapy, Adjuvant therapy) in China (IV) before January 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top